AAPL349.73+1.51 (+0.43%) ▲|ABBV283.49-1.45 (-0.51%) ▼|ABT102.40-0.12 (-0.11%) ▼|ACN245.90-12.84 (-4.96%) ▼|ADBE266.96-3.59 (-1.33%) ▼|AMAT376.93+1.35 (+0.36%) ▲|AMD516.69+8.76 (+1.72%) ▲|AMGN440.77-6.51 (-1.46%) ▼|AMT192.35+10.78 (+5.94%) ▲|AMZN248.56-1.82 (-0.73%) ▼|AVGO324.87+1.63 (+0.50%) ▲|AXP315.83-9.34 (-2.87%) ▼|BA185.04-2.51 (-1.34%) ▼|BAC50.68-0.40 (-0.78%) ▼|BKNG157.29-3.81 (-2.37%) ▼|BLK1,121.22-16.08 (-1.41%) ▼|BMY61.77-1.23 (-1.95%) ▼|BNY144.11-1.21 (-0.83%) ▼|BRK-B545.91-1.07 (-0.19%) ▼|C120.89-1.62 (-1.32%) ▼|CAT683.80-20.26 (-2.88%) ▼|CL94.85-2.55 (-2.61%) ▼|CMCSA22.81-0.03 (-0.13%) ▼|COF200.80-2.64 (-1.30%) ▼|COP150.53+4.90 (+3.36%) ▲|COST1,010.61-7.60 (-0.75%) ▼|CRM245.87-4.43 (-1.77%) ▼|CSCO105.68+0.79 (+0.75%) ▲|CVS93.66-0.82 (-0.87%) ▼|CVX230.56+3.88 (+1.71%) ▲|DE635.53-8.10 (-1.26%) ▼|DHR226.74-3.01 (-1.31%) ▼|DIS112.11-1.02 (-0.90%) ▼|DUK124.40-1.01 (-0.80%) ▼|EMR158.70-1.59 (-0.99%) ▼|FDX296.83-7.10 (-2.33%) ▼|GD346.85-3.95 (-1.12%) ▼|GE284.21-9.33 (-3.18%) ▼|GEV807.01-20.41 (-2.47%) ▼|GILD156.36-0.84 (-0.53%) ▼|GM75.19-2.02 (-2.62%) ▼|GOOG320.81+0.05 (+0.01%) ▲|GOOGL323.99-0.23 (-0.07%) ▼|GS882.41-8.89 (-1.00%) ▼|HD319.03-8.70 (-2.65%) ▼|HON212.59-5.72 (-2.62%) ▼|IBM252.08-0.03 (-0.01%) ▼|INTC86.50+1.01 (+1.18%) ▲|INTU349.29-5.62 (-1.58%) ▼|ISRG452.05+8.20 (+1.85%) ▲|JNJ263.59-4.03 (-1.50%) ▼|JPM331.33-5.21 (-1.55%) ▼|KO93.27-2.08 (-2.18%) ▼|LIN505.84-4.52 (-0.89%) ▼|LLY1,277.92-28.77 (-2.20%) ▼|LMT593.98+4.07 (+0.69%) ▲|LOW198.83-5.55 (-2.71%) ▼|LRCX227.65-2.51 (-1.09%) ▼|MA623.08-10.14 (-1.60%) ▼|MCD248.54-4.09 (-1.62%) ▼|MDLZ63.93-1.26 (-1.93%) ▼|MDT95.79-0.80 (-0.83%) ▼|META644.37-4.48 (-0.69%) ▼|MMM170.98-4.58 (-2.61%) ▼|MO75.18-0.89 (-1.17%) ▼|MRK144.14-3.10 (-2.10%) ▼|MS181.46-2.52 (-1.37%) ▼|MSFT523.07+1.99 (+0.38%) ▲|MU881.87+25.38 (+2.96%) ▲|NEE81.43-0.48 (-0.58%) ▼|NFLX67.03-0.02 (-0.03%) ▼|NKE37.49-0.83 (-2.17%) ▼|NOW155.52-1.48 (-0.94%) ▼|NVDA212.66+0.45 (+0.21%) ▲|ORCL126.20+0.66 (+0.52%) ▲|PEP135.89-2.94 (-2.12%) ▼|PFE29.90-0.52 (-1.71%) ▼|PG162.04-2.46 (-1.50%) ▼|PLTR194.70-1.50 (-0.76%) ▼|PM201.34-0.40 (-0.20%) ▼|QCOM173.80+0.97 (+0.56%) ▲|RTX190.57-4.14 (-2.13%) ▼|SBUX101.23-0.68 (-0.67%) ▼|SCHW90.31-1.13 (-1.24%) ▼|SO93.14-0.69 (-0.73%) ▼|SPG211.43-0.61 (-0.29%) ▼|T21.53-1.22 (-5.34%) ▼|TMO667.70-8.84 (-1.31%) ▼|TMUS152.48-6.32 (-3.98%) ▼|TSLA372.08-2.51 (-0.67%) ▼|TXN281.50+2.00 (+0.72%) ▲|UBER67.71-1.36 (-1.97%) ▼|UNH421.78-3.21 (-0.75%) ▼|UNP289.88-8.22 (-2.76%) ▼|UPS99.36-2.16 (-2.13%) ▼|USB59.13-0.89 (-1.48%) ▼|V407.29-7.05 (-1.70%) ▼|VZ43.92-1.28 (-2.83%) ▼|WFC82.00-1.01 (-1.22%) ▼|WMT120.23-0.89 (-0.73%) ▼|XOM181.49+3.26 (+1.83%) ▲|AAPL349.73+1.51 (+0.43%) ▲|ABBV283.49-1.45 (-0.51%) ▼|ABT102.40-0.12 (-0.11%) ▼|ACN245.90-12.84 (-4.96%) ▼|ADBE266.96-3.59 (-1.33%) ▼|AMAT376.93+1.35 (+0.36%) ▲|AMD516.69+8.76 (+1.72%) ▲|AMGN440.77-6.51 (-1.46%) ▼|AMT192.35+10.78 (+5.94%) ▲|AMZN248.56-1.82 (-0.73%) ▼|AVGO324.87+1.63 (+0.50%) ▲|AXP315.83-9.34 (-2.87%) ▼|BA185.04-2.51 (-1.34%) ▼|BAC50.68-0.40 (-0.78%) ▼|BKNG157.29-3.81 (-2.37%) ▼|BLK1,121.22-16.08 (-1.41%) ▼|BMY61.77-1.23 (-1.95%) ▼|BNY144.11-1.21 (-0.83%) ▼|BRK-B545.91-1.07 (-0.19%) ▼|C120.89-1.62 (-1.32%) ▼|CAT683.80-20.26 (-2.88%) ▼|CL94.85-2.55 (-2.61%) ▼|CMCSA22.81-0.03 (-0.13%) ▼|COF200.80-2.64 (-1.30%) ▼|COP150.53+4.90 (+3.36%) ▲|COST1,010.61-7.60 (-0.75%) ▼|CRM245.87-4.43 (-1.77%) ▼|CSCO105.68+0.79 (+0.75%) ▲|CVS93.66-0.82 (-0.87%) ▼|CVX230.56+3.88 (+1.71%) ▲|DE635.53-8.10 (-1.26%) ▼|DHR226.74-3.01 (-1.31%) ▼|DIS112.11-1.02 (-0.90%) ▼|DUK124.40-1.01 (-0.80%) ▼|EMR158.70-1.59 (-0.99%) ▼|FDX296.83-7.10 (-2.33%) ▼|GD346.85-3.95 (-1.12%) ▼|GE284.21-9.33 (-3.18%) ▼|GEV807.01-20.41 (-2.47%) ▼|GILD156.36-0.84 (-0.53%) ▼|GM75.19-2.02 (-2.62%) ▼|GOOG320.81+0.05 (+0.01%) ▲|GOOGL323.99-0.23 (-0.07%) ▼|GS882.41-8.89 (-1.00%) ▼|HD319.03-8.70 (-2.65%) ▼|HON212.59-5.72 (-2.62%) ▼|IBM252.08-0.03 (-0.01%) ▼|INTC86.50+1.01 (+1.18%) ▲|INTU349.29-5.62 (-1.58%) ▼|ISRG452.05+8.20 (+1.85%) ▲|JNJ263.59-4.03 (-1.50%) ▼|JPM331.33-5.21 (-1.55%) ▼|KO93.27-2.08 (-2.18%) ▼|LIN505.84-4.52 (-0.89%) ▼|LLY1,277.92-28.77 (-2.20%) ▼|LMT593.98+4.07 (+0.69%) ▲|LOW198.83-5.55 (-2.71%) ▼|LRCX227.65-2.51 (-1.09%) ▼|MA623.08-10.14 (-1.60%) ▼|MCD248.54-4.09 (-1.62%) ▼|MDLZ63.93-1.26 (-1.93%) ▼|MDT95.79-0.80 (-0.83%) ▼|META644.37-4.48 (-0.69%) ▼|MMM170.98-4.58 (-2.61%) ▼|MO75.18-0.89 (-1.17%) ▼|MRK144.14-3.10 (-2.10%) ▼|MS181.46-2.52 (-1.37%) ▼|MSFT523.07+1.99 (+0.38%) ▲|MU881.87+25.38 (+2.96%) ▲|NEE81.43-0.48 (-0.58%) ▼|NFLX67.03-0.02 (-0.03%) ▼|NKE37.49-0.83 (-2.17%) ▼|NOW155.52-1.48 (-0.94%) ▼|NVDA212.66+0.45 (+0.21%) ▲|ORCL126.20+0.66 (+0.52%) ▲|PEP135.89-2.94 (-2.12%) ▼|PFE29.90-0.52 (-1.71%) ▼|PG162.04-2.46 (-1.50%) ▼|PLTR194.70-1.50 (-0.76%) ▼|PM201.34-0.40 (-0.20%) ▼|QCOM173.80+0.97 (+0.56%) ▲|RTX190.57-4.14 (-2.13%) ▼|SBUX101.23-0.68 (-0.67%) ▼|SCHW90.31-1.13 (-1.24%) ▼|SO93.14-0.69 (-0.73%) ▼|SPG211.43-0.61 (-0.29%) ▼|T21.53-1.22 (-5.34%) ▼|TMO667.70-8.84 (-1.31%) ▼|TMUS152.48-6.32 (-3.98%) ▼|TSLA372.08-2.51 (-0.67%) ▼|TXN281.50+2.00 (+0.72%) ▲|UBER67.71-1.36 (-1.97%) ▼|UNH421.78-3.21 (-0.75%) ▼|UNP289.88-8.22 (-2.76%) ▼|UPS99.36-2.16 (-2.13%) ▼|USB59.13-0.89 (-1.48%) ▼|V407.29-7.05 (-1.70%) ▼|VZ43.92-1.28 (-2.83%) ▼|WFC82.00-1.01 (-1.22%) ▼|WMT120.23-0.89 (-0.73%) ▼|XOM181.49+3.26 (+1.83%) ▲|
10.7 C
New York
Friday, October 23, 2026

Tag: drug

newsFORsourcecompanycontentinformation1releasesmarket

Cellarity Initiates Phase 1 Clinical Study of CLY-124, a First-in-Class Globin-Switching Oral Medicine for the Treatment of Sickle Cell Disease

Initiation follows successful IND clearance based on preclinical data package indicating robust increase in fetal hemoglobin with no cytotoxicity Novel Globin-Switching mechanism derived from...

ProFound Therapeutics Announces Multi-Year Strategic Collaboration with Novartis to Discover and Develop Novel Therapeutics for Cardiovascular Disease

ProFound to receive $25M in upfront and near-term milestone payments with a potential value from downstream milestones of $750M per target

BioArctic: Professor Lars Lannfelt to receive the 2025 Hartwig Piepenbrock-DZNE Prize

STOCKHOLM, June 26, 2025 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) announced today that BioArctic's founder, Professor Lars Lannfelt, will receive the 2025...

Oncorena’s new issue of shares fully subscribed

LUND, Sweden, June 26, 2025 /PRNewswire/ -- Today, Oncorena communicates that the new issue of shares was fully subscribed to a sum of 133 million...

Oncorena’s new issue of shares fully subscribed

LUND, Sweden, June 26, 2025 /PRNewswire/ -- Today, Oncorena communicates that the new issue of shares was fully subscribed to a sum of 133 million...

Mind Vault Introduces Senior Cognitive Health Update: Brain Support Formula Highlights Age-Focused Innovation

Cognitive Wellness Announcement Highlights New Senior Brain Health Formulation with Scientifically Backed Ingredients 
Cognitive Wellness Announcement Highlights New Senior Brain Health Formulation with Scientifically Backed Ingredients

Audifort Update Reveals Breakthrough Botanical Formulation for Hearing Health Support in 2025

Plant-Based Daily Formula Updated in 2025 to Support Holistic Hearing Wellness and Lifestyle Resilience 
Plant-Based Daily Formula Updated in 2025 to Support Holistic Hearing Wellness and Lifestyle Resilience

Hummingbird Bioscience Licenses HMBD-002, Phase II-Ready Anti-VISTA Monoclonal Antibody to Percheron Therapeutics

Percheron Therapeutics obtains exclusive worldwide rights to Hummingbird Bioscience’s HMBD-002 for further clinical development

Iovance’s (IOVA) CFO Resigns Amid Launch Setbacks and Legal Pressure– Hagens Berman

SAN FRANCISCO, June 25, 2025 (GLOBE NEWSWIRE) -- Biotechnology firm Iovance Biotherapeutics Inc. (NASDAQ: IOVA) announced a significant leadership transition, confirming the resignation of Chief Financial Officer Jean-Marc Bellemin, effective July 10, 2025. Mr. Bellemin, who assumed the CFO role in November 2020, is reportedly departing to pursue other endeavors, according to a regulatory filing. Bellemin’s exit comes at a tumultuous time, as the company is grappling with a recent commercial setback for its flagship drug, Amtagvi, and the specter of a class-action securities lawsuit.

BioCity’s ETA-Selective Antagonist SC0062 Granted Breakthrough Therapy Designation in China for Diabetic Kidney Disease with Albuminuria

Second BTD Recognition Highlights Compound's Potential as Next-Generation Broad-Spectrum Renal TherapySHANGHAI, June 25, 2025 /PRNewswire/ -- BioCity Biopharma ("BioCity") announced today that the Center for...

CARsgen Therapeutics Announces NDA Acceptance of Satri-cel by China’s NMPA

SHANGHAI, June 25, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that...

Altimmune to Announce Topline 24 Week Results from its IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH on Thursday, June 26

Company to host Investor Webcast on Thursday, June 26, 2025, at 8:30 am E.T. 
Company to host Investor Webcast on Thursday, June 26, 2025, at 8:30 am E.T.

Rakovina Therapeutics Announces Results from 2025 Annual General Meeting

VANCOUVER, British Columbia, June 25, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0) (“Rakovina” or the “Company”), a biopharmaceutical company advancing next-generation cancer therapies through artificial intelligence (AI)-powered drug discovery is pleased to announce the results of voting at its 2025 annual general meeting of shareholders held on June 25, 2025, in Vancouver, British Columbia (the “Meeting”).

Appili Therapeutics Reports Fiscal Year 2025 Financial and Operational Results

LIKMEZ™ (ATI-1501) for Metronidazole Oral Suspension 500mg/5mL re-launched and commercial sales ongoing  

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsDrug

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers